v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:    
Research and development $ 50,575 $ 28,429
Acquired in-process research and development 12,500 0
General and administrative 15,402 11,946
Total operating expenses 78,477 40,375
Interest income (4,065) 0
Other income (464) (354)
Loss before provision (benefit) for income taxes (73,948) (40,021)
Provision (benefit) for income taxes (11) 352
Net loss $ (73,937) $ (40,373)
Net loss per common share - basic (in dollars per share) $ (0.57) $ (0.35)
Net loss per common share - diluted (in dollars per share) $ (0.57) $ (0.35)
Weighted-average common shares outstanding – basic (in shares) 130,503,264 116,557,508
Weighted-average common shares outstanding – diluted (in shares) 130,503,264 116,557,508

Source